A groundbreaking study led by researchers from the University of Eastern Finland and the University of Oulu has unveiled a significant and previously underestimated connection between frontotemporal dementia (FTD) and epilepsy. Published in the prestigious medical journal JAMA Neurology, the findings suggest that epileptic seizures are far more prevalent among FTD patients than clinical literature has historically indicated. This discovery not only refines the scientific understanding of the symptoms associated with this complex neurodegenerative disorder but also underscores a critical shift in how clinicians should monitor and treat patients diagnosed with, or at risk of, FTD.
The project, coordinated by Neurocenter Finland, stands as one of the largest investigations of its kind globally. By analyzing an extensive dataset spanning over a decade, researchers have provided robust evidence that epilepsy—a condition often associated with other forms of dementia, such as Alzheimer’s—is a frequently overlooked component of the FTD clinical landscape. This new information is expected to reshape diagnostic protocols and emphasize the necessity of screening for seizure activity in patients presenting with cognitive or behavioral decline.
Epilepsy as an Early Warning Sign
One of the most striking revelations of the study is the timing of seizure onset. The researchers found that in a subset of patients, epileptic seizures manifested years before the formal diagnosis of frontotemporal dementia was even established. This suggests that seizure activity may, in some instances, serve as a precursor or an early clinical marker for the underlying neurodegenerative process.
For years, the medical community has recognized a well-documented link between Alzheimer’s disease and epilepsy. However, data regarding the interplay between FTD and seizure disorders has remained notoriously scarce. The current study, which analyzed patient data from the university hospitals of Kuopio and Oulu between 2010 and 2021, successfully closes this knowledge gap. By reviewing 12,490 medical records, the team identified 245 patients with FTD and 1,326 patients with Alzheimer’s disease, comparing them against a group of healthy control subjects to establish a clear statistical baseline.
"Our results show that epilepsy is considerably more common among those with FTD than those with Alzheimer’s disease or in healthy controls," explains Doctoral Researcher Annemari Kilpeläinen, the first author of the research article and a medical specialist in neurology.
The data indicates that the prevalence of epilepsy is not static but tends to increase as the disease progresses. When assessing patients at various time points—ranging from a decade before a dementia diagnosis to five years after—the researchers noted a steady upward trend. By the five-year post-diagnosis mark, approximately 11% of FTD patients were found to have epilepsy. Beyond official clinical diagnoses, the researchers also tracked the prescription of anti-seizure medications, which were significantly more common among the FTD cohort, further reinforcing the reliability of the study’s conclusions. Perhaps most notably, the researchers observed that epilepsy was more prevalent across all stages of the disease than any previous international study had suggested.
The Challenge of Diagnosis and Treatment
The intersection of FTD and epilepsy presents a unique diagnostic hurdle for clinicians. Because frontotemporal dementia is primarily characterized by changes in behavior, personality, and language, the clinical presentation can often mimic the symptoms of an epileptic seizure, or vice-versa. This overlap often leads to underdiagnosis or the misattribution of symptoms, which in turn delays the administration of appropriate neurological care.
The implications of missing an epilepsy diagnosis in an FTD patient are profound. Untreated seizures can lead to further cognitive decline, physical injury, and a general reduction in the patient’s functional capacity. Addressing these seizures is not merely about symptom management; it is a vital step in maintaining the patient’s quality of life and preventing unnecessary deterioration.
"Identifying epilepsy is important because its treatment can improve patients’ functional capacity and quality of life," says Associate Professor Eino Solje, the project’s principal investigator and Director of the UEF Brain Research Unit. "Knowledge about the association between epilepsy and FTD raises new research questions: do these diseases share some pathophysiological mechanisms, and could some FTD symptoms be caused by alterations in the specific electrical systems of the brain?"
This line of inquiry opens the door to future research that could fundamentally change how the medical community views neurodegeneration. If specific electrical alterations in the brain are found to be driving certain FTD symptoms, researchers may be able to develop targeted interventions that stabilize brain activity, potentially slowing the progression of the disease or alleviating its most distressing manifestations.
A Multidisciplinary Approach to Neurodegeneration
The study’s success is attributed to its massive scale and the collaborative nature of the research. By combining real-life patient data with unique, high-quality medical registers, the project demonstrates the power of cross-disciplinary cooperation. The research involved a synergy between the University of Oulu and the University of Eastern Finland, drawing on expertise from various fields, including medicine and law, to ensure the integrity and ethical application of the patient data.
Furthermore, the participation of Kuopio University Hospital and Oulu University Hospital highlights the project’s international relevance. Both institutions are recognized members of the European Reference Network EpiCARE, a prestigious network dedicated to the treatment and research of rare and complex epilepsies. This association ensures that the findings are not only robust but also aligned with the highest standards of international neurological care.
As the findings from this study begin to permeate the global neurological community, the focus is likely to shift toward more proactive monitoring. Clinicians are now urged to maintain a high index of suspicion for epilepsy when treating patients with FTD. By integrating regular EEG monitoring or closer clinical observation for seizure-like activity, healthcare providers may be able to offer more comprehensive care plans that address the dual challenge of dementia and epilepsy.
The study serves as a poignant reminder that in the complex landscape of neurodegenerative diseases, every symptom matters. What was once considered an isolated or rare comorbidity in FTD is now revealed to be a significant feature of the disease’s clinical profile. Through the meticulous work of the Finnish research team, the medical community has gained a clearer, more nuanced view of frontotemporal dementia, providing a foundation for future breakthroughs that may eventually improve outcomes for patients and their families.
Ultimately, this project highlights the necessity of viewing the brain as an interconnected system where electrical activity and structural health are inextricably linked. As researchers continue to probe the pathophysiological mechanisms connecting FTD and epilepsy, the path toward more effective, personalized treatment for those suffering from memory disorders continues to sharpen, offering a glimmer of hope in the ongoing effort to demystify and manage neurodegenerative conditions.
